Macro Commentary - Chinese policymakers are signaling a strategic shift to prioritize domestic demand as the primary economic task by 2026, addressing issues like overcapacity, deflationary pressures, and weak confidence [2] - Demand-side policies will focus on stabilizing the real estate market and boosting consumption through measures such as lowering mortgage rates and purchasing unsold properties [2] - Supply-side policies will aim at structural adjustments, enhancing industry concentration by curbing capacity expansion and encouraging mergers and acquisitions [6] Market Performance - The Hang Seng Index closed at 27,968, up 0.51% for the day and 9.12% year-to-date, while the Hang Seng Tech Index fell by 1.00% [3] - The Chinese stock market saw gains, particularly in real estate, consumer staples, and financial sectors, with net inflows of 4.374 billion HKD from southbound funds [5] - The U.S. stock market experienced a pullback, with technology, consumer discretionary, and materials sectors leading the decline, while communication services, real estate, and energy sectors gained [5] Company Insights - Meta (META US) reported a 24% year-on-year revenue increase to 59.9 billion USD for Q4 2025, driven by AI-enhanced advertising growth, and provided a revenue guidance of 53.5-56.5 billion USD for Q1 2026 [6] - Microsoft (MSFT US) achieved 16.7% revenue growth to 81.3 billion USD in Q2 FY26, with strong performance in productivity and business processes, and provided a target price of 614.6 USD [6] - ServiceNow (NOW US) reported a 21% revenue increase to 3.57 billion USD for Q4 2025, with a positive outlook for FY26 driven by AI efficiencies, maintaining a target price of 215.0 USD [7][8] - Sunny Optical Technology (2382 HK) expects a 70-75% increase in net profit for 2025, driven by high-end camera upgrades and growth in automotive and smart glasses segments, with a target price of 91.38 HKD [8]

Market Performance - The Hang Seng Index closed at 27,827, up 2.58% for the day and 8.57% year-to-date [1] - The Hang Seng Tech Index rose by 2.53%, with a year-to-date increase of 6.96% [1] - The Shanghai Composite Index saw a modest increase of 0.27%, with a year-to-date rise of 4.60% [1] - The US markets showed mixed results, with the Dow Jones up 0.02% and the S&P 500 down 0.01% [1] Sector Performance - In the Hong Kong market, the Hang Seng Financial Index increased by 2.62%, while the Hang Seng Real Estate Index rose by 3.03%, reflecting strong performance in these sectors [2] - The Chinese stock market saw gains in materials, energy, and telecommunications, while consumer staples, utilities, and healthcare lagged [3] Company Insights - New Oriental (EDU US) reported a 15% year-on-year revenue growth to $1.19 billion, exceeding Bloomberg consensus estimates by 3% [5] - The company’s non-GAAP operating profit surged by 207% to $89.13 million, driven by improved operational efficiency and utilization in its education business [5] - New Oriental raised its revenue guidance for FY26E to a range of $5.29 billion to $5.49 billion, indicating a year-on-year growth of 8%-12% [5] Economic Indicators - The USD/CNY exchange rate fluctuated around 6.94, indicating stability in the currency market [3] - The US Federal Reserve maintained interest rates, with indications of a hawkish stance in future meetings, suggesting economic activity is expanding steadily [3][4]

Investment Rating - The report maintains a "BUY" rating on New Oriental, indicating a strong core educational business, solid margin expansion trend, and attractive shareholder return [1][18]. Core Insights - New Oriental's 2QFY26 results exceeded expectations, with net revenue increasing by 15% YoY to US$1.19 billion, surpassing Bloomberg consensus estimates by 3% [1]. - Non-GAAP operating income surged by 207% YoY to US$89.13 million, significantly beating the consensus estimate of US$54.87 million, driven by enhanced operational efficiency [1]. - The management anticipates net revenue growth of 11-14% YoY for 3QFY26E, raising the FY26E net revenue forecast to US$5.29-5.49 billion, reflecting solid momentum in new educational and high-school tutoring businesses [1]. Financial Performance - Revenue projections for FY26E are set at US$5.47 billion, with a YoY growth of 11.6%, and adjusted net profit is expected to reach US$594.2 million [2]. - The report forecasts a continued revenue growth trajectory, with FY27E and FY28E revenues projected at US$5.99 billion and US$6.46 billion, respectively [2]. - Non-GAAP operating profit margin (OPM) is expected to expand to 12.8% in 3QFY26E, up from 7.5% in 2QFY26, indicating improved operational efficiency [9][10]. Valuation - The target price for New Oriental is set at US$78.00, reflecting a 32.3% upside from the current price of US$58.95 [3]. - The valuation is derived from a sum-of-the-parts (SOTP) analysis, with the educational and consulting business valued at US$75.00 based on a 25x FY26E PE ratio [12][13]. - The report highlights a strong growth outlook for the educational segment, with a revenue CAGR of 10% expected from FY26 to FY28 [13].

Group 1: Market Overview - The Hang Seng Index closed at 27,127, up 1.35% for the day and 5.84% year-to-date [1] - The Hang Seng Financial Index rose by 2.51% for the day and 5.88% year-to-date, indicating strong performance in the financial sector [2] - Southbound capital recorded a net sell of 635 million HKD, with notable sell-offs in China Mobile, Zijin Mining, and SMIC, while Tencent and Longi Green Energy saw significant net buying [3] Group 2: Company Analysis - Sanofi - Sanofi's collaboration with Pfizer on the 707/PF'4404 (PD-1/VEGF) has advanced rapidly, with plans to initiate four global Phase III clinical trials by 2026 covering five major indications [4] - The dual antibody PD-(L)1/VEGF is expected to become a cornerstone in next-generation tumor immunotherapy, with Sanofi leveraging its internal pipeline for competitive advantage [5] - Sanofi's robust pipeline includes multiple candidates, with the potential for early assets to be licensed out as clinical data matures [6] Group 3: Financial Projections - The target price for Sanofi is set at 37.43 HKD, based on a DCF model with a WACC of 10.11% and a perpetual growth rate of 2.0% [7] - The company is estimated to have net cash of approximately 13 billion HKD, supporting its growth and development initiatives [7]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 37.43, representing a potential upside of 55.5% from the current price of HKD 24.08 [2][8]. Core Insights - Pfizer is rapidly advancing the global clinical development of 707/PF'4404 (PD-1/VEGF), with plans to initiate four Phase III trials in 2026 targeting five major indications. This development is expected to position Pfizer favorably in the competitive landscape of next-generation cancer immunotherapy [1][8]. - The collaboration between Pfizer and the company is anticipated to unlock significant global value for 707/PF'4404, serving as a key catalyst for the company's upward trajectory [1][8]. - The company is also increasing its R&D investments, with multiple pipelines expected to yield clinical data soon, enhancing the potential for external licensing opportunities [8][12]. Financial Summary - For FY23A, the company reported sales revenue of RMB 7,816 million, with a year-on-year growth of 13.8%. Projections for FY24A and FY25E are RMB 9,108 million and RMB 17,972 million, respectively, indicating a significant growth trajectory [2][15]. - The net profit attributable to shareholders for FY23A was RMB 1,549 million, reflecting a decline of 19.1% year-on-year, but is expected to rebound to RMB 2,090 million in FY24A and surge to RMB 9,741 million in FY25E, marking a growth of 366.0% [2][15]. - The earnings per share (EPS) for FY25E is projected at RMB 3.84, with a price-to-earnings (P/E) ratio of 5.6, indicating a strong valuation relative to earnings [2][15]. Market Position and Shareholder Structure - The company's market capitalization stands at HKD 61,115.2 million, with a 52-week stock price range of HKD 35.90 to HKD 6.01 [3][4]. - Major shareholders include TMF (Cayman) Ltd. with 22.8% and Decade Sunshine with 19.6%, indicating a concentrated ownership structure [4]. Clinical Development and Pipeline - The report highlights the competitive landscape for PD-(L)1/VEGF therapies, with Pfizer's strategy of combining IO with ADCs (antibody-drug conjugates) as a unique advantage [1][8]. - The company has several promising candidates in its pipeline, including 705 (PD-1/HER2) and 706 (PD-1/PD-L1), which are currently in Phase II trials in China [8][12]. Valuation and Forecast Adjustments - The report adjusts the financial forecasts for FY25E and FY26E, reflecting a slight increase in revenue expectations due to the anticipated success of the 707 program [12][13]. - The DCF valuation analysis estimates a per-share value of HKD 37.43, based on a weighted average cost of capital (WACC) of 10.11% and a perpetual growth rate of 2.0% [13][14].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 37.43, representing a potential upside of 55.5% from the current price of HKD 24.08 [2][8]. Core Insights - Pfizer is rapidly advancing the global clinical development of 707/PF'4404 (PD-1/VEGF), with plans to initiate four global Phase III trials in 2026 targeting five major indications. The combination of PD-(L)1/VEGF dual antibodies is expected to become a cornerstone of next-generation cancer immunotherapy, positioning Pfizer to leverage its internal pipeline synergy and strong clinical execution capabilities [1][8]. - The company is increasing its R&D investments, with several pipelines expected to yield clinical data soon. The core business fundamentals remain robust, providing a safety margin, and the company is projected to achieve significant revenue growth driven by its innovative pipeline [8][12]. Financial Summary - For FY23A, the company reported sales revenue of RMB 7,816 million, with a year-on-year growth of 13.8%. The projected sales revenue for FY25E is RMB 17,972 million, reflecting a substantial increase of 97.3% [2][15]. - The net profit attributable to shareholders for FY23A was RMB 1,549 million, with a year-on-year decline of 19.1%. However, the forecast for FY25E shows a significant increase to RMB 9,741 million, indicating a growth of 366.0% [2][15]. - The earnings per share (EPS) for FY23A was RMB 0.64, expected to rise to RMB 3.84 in FY25E [2][15]. Market Position and Shareholder Structure - The company's market capitalization is approximately HKD 61,115.2 million, with a 52-week stock price range of HKD 35.90 to HKD 6.01 [3][4]. - Major shareholders include TMF (Cayman) Ltd. with 22.8% and Decade Sunshine with 19.6% [4]. Clinical Development and Pipeline - The report highlights the competitive landscape for PD-(L)1/VEGF therapies, with Pfizer's strategy of combining IO with ADCs as a unique advantage. The company plans to conduct multiple Phase III trials for various indications, including NSCLC and mCRC, with a focus on rapid patient recruitment [1][8]. - The ongoing clinical trials for other innovative products, such as 705 (PD-1/HER2) and 706 (PD-1/PD-L1), are also expected to contribute to the company's growth and potential licensing opportunities [8][12].

Market Overview - Global markets showed mixed performance, with the Hang Seng Index closing at 26,766, up 0.06% for the day and up 4.43% year-to-date [1] - The US markets saw gains, with the Dow Jones up 0.64% and the S&P 500 up 0.50%, while the Nasdaq increased by 0.43% [1] - The Chinese stock market exhibited mixed results, with A-shares declining, particularly in defense, automotive, and social services sectors, while non-ferrous metals, oil, and coal sectors showed gains [3] Sector Performance - In the Hong Kong market, the Hang Seng Financial Index rose by 0.74%, while the Hang Seng Real Estate Index increased by 1.84%, indicating strong performance in these sectors [2] - Conversely, the Hang Seng Industrial Index fell by 0.44%, reflecting weaker performance in industrial stocks [2] Company Analysis - China Resources Beverage (2460 HK) is projected to see a 35.5% decline in net profit for FY2025, estimated at RMB 1.06 billion, primarily due to increased marketing expenditures and slower capacity expansion [4] - Despite the anticipated profit drop, there are positive indicators such as a new experienced chairman likely to drive significant reforms, and potential increases in dividend payouts [4] - The report maintains a "Buy" rating for China Resources Beverage, with a target price adjusted down by 8% to HKD 11.87, reflecting the earnings downgrade [4]

Investment Rating - The report maintains a Buy rating for CR Beverage with a target price of HK$11.87, reflecting an 8% decrease from the previous target price of HK$12.85 [1][3]. Core Insights - The forecast for CR Beverage's FY25E net profit is a decline of 35.5% to RMB1.06 billion, with a more significant drop expected in the second half of FY25E due to large marketing contracts and increased supply chain investments [1]. - The company is expected to experience pressure release in 2025, with better growth anticipated during the 15th Five-Year Plan period, potentially starting as early as 2026 [1][9]. - Key positive developments include the appointment of a new Chairman with extensive experience expected to drive significant reforms, particularly in sales [1][9]. - The company is considering increasing its dividend payout ratio in light of weaker performance in 2025 [1][9]. Financial Summary - Revenue for FY25E is projected at RMB11.46 billion, a decrease of 15.2% year-on-year, with a recovery expected in FY26E with 8.3% growth [2][10]. - Net profit for FY25E is expected to be RMB1.06 billion, down from RMB1.64 billion in FY24A, with a recovery to RMB1.29 billion in FY26E [2][10]. - The company's P/E ratio for FY25E is projected at 17.9x, with a decrease in net profit margin to 9.2% [2][10]. Market Position and Share Performance - CR Beverage's market capitalization is approximately HK$24.46 billion, with a current share price of HK$10.20, indicating a potential upside of 16.4% to the target price [3][4]. - The company's packaged water market share has stabilized, showing slight growth at the end of Q3 [9]. - The share performance over the past six months has seen a decline of 21.5% [6].

Report Summary 1. Report Industry Investment Rating - No industry investment rating is provided in the report. 2. Core Viewpoints - The market shows mixed trends across different regions and sectors in the fixed - income market. Some bonds tightened, while others widened or had price changes due to various factors such as demand, profit - taking, and company - specific news [2]. - The analysts maintain a buy rating on BBLTB's subordinated bonds, expecting the bank to call its subordinated bonds on the first call dates due to sufficient capital buffer and past redemption records [7]. 3. Summary by Relevant Catalogs Trading Desk Comments - **Chinese IG Space**: CCAMCL/ORIEAS 2 - 5yr bonds tightened 3 - 5bps due to onshore demand, AMs/prop desks bought FRESHK/ZHOSHK which tightened 1 - 3bps, LIFUNGs gained 0.1 - 0.4pt, EHICAR 26 - 27 were 0.4pt higher [2]. - **Chinese/HK Properties**: ROADKG bonds and perps rose 0.7 - 1.5pts, SHUION 29 gained 0.3pt, FUTLAN 28/LNGFOR 27 - 32s closed 0.5 - 1.2pts higher, VDNWDL/NWDEVL complex were 0.2pt lower to 0.3pt higher, VNKRLE 27 - 29 were 0.3pt higher [2]. - **KR Space**: HYNMTR FRNs tightened 3 - 5bps as onshore/offshore buyers sought loose bonds and dealer inventory dried up [2]. - **JP Space**: NTT 35/MUFG 35s/SOBKCO 35/SMBCAC 35 tightened 1 - 4bps, NOMURA 7 Perp traded 0.1pt lower, RESLIF 6.875 Perp closed 0.1pt higher [2]. - **SE Asia Space**: OCBCSP 32/35s tightened 1 - 3bps, light selling on OCBCSP 34s, KBANK 31/UOBSP 31 - 32s/BBLTB T2s were 1bp tighter to 2bp wider, ReNew Energy complex edged 0.1 - 0.3pt higher, SMCGL Perps/INDYIJ 29s/MEDCIJ 26 - 30s were unchanged to 0.2pt higher, TOPTB 6.1 Perp lost 0.1pt [2]. - **Middle East**: BSFR 35s and long - end KSAs softened 0.1 - 0.3pt lower, SECO 29 - 36s traded active two - way and closed 1 - 2bps wider, ARAMCO 30 - 31s were 1 - 2bps wider, LGFV edged a touch tighter overall [2]. - **Morning Price Movements**: JP AT1s and insurance subs had two - way flows but stable prices, HUXJDP 26 rose 0.9pt, CRNAU 29/HYSAN 4.85 Perp were 0.6 - 0.7pt higher, LNGFOR 28/FTLNHD 27/SOFTBK 31 were 0.5 - 0.8pt lower [3]. Top Performers and Underperformers - **Top Performers**: ROADKG bonds had significant price increases, with ROADKG 6.7 03/30/28 rising 1.5 to 22.9, ROADKG 5 1/8 01/26/30 rising 1.4 to 22.8, etc [4]. - **Top Underperformers**: GARUDA 6 1/2 12/28/31 fell 1.9 to 90.0, ADSEZ 5 08/02/41 fell 1.5 to 87.3, etc [4]. Macro News Recap - Last Friday, S&P was up 0.03%, Dow was down 0.58%, and Nasdaq was up 0.28%. US Jan'26 S&P Global Services PMI was 52.5 (lower than expected), Manufacturing PMI was 51.9 (as expected). UST yield was lower, with 2/5/10/30 - year yields at 3.60%/3.84%/4.24%/4.82% [6]. Desk Analyst Comments on BBLTB - FY25 investment gains offset lower NII and net fee income. Analysts maintain a buy on BBLTB 3.466 09/23/36 and BBLTB 6.056 03/25/40, expecting first - call redemptions [7]. - FY25 results softened: operating profit before tax lowered by 1% to THB56.0bn, net interest income decreased 8% to THB123.6bn, NIM dropped to 2.8% from 3.1% in FY24, net fee income decreased 2% to THB27.2bn, total operating income rose 2% to THB178.5bn, cost - to - income ratio rose slightly to 48.4% [8][9]. - Asset quality deteriorated slightly: NPL ratio increased to 3.0% as of Dec'25 from 2.7% as of Dec'24, NPL coverage ratio decreased to 324% from 334%. However, capital adequacy is solid, with standalone/consolidated CET 1 and Tier 1 ratios increasing [10]. Offshore Asia New Issues - **Priced**: Ma'aden Sukuk Ltd issued USD1000mn 10 - yr bonds with a 5.25% coupon at T + 105, rated Baa1/ - /BBB+ [12]. - **Pipeline**: The Link Finance (Cayman) 2009 plans to issue 10 - yr USD bonds at T + 105, with an issue rating of - /A/ - [13]. News and Market Color - **Onshore Primary Issuances**: 110 credit bonds were issued last Friday with an amount of RMB95bn. Month - to - date, 1,485 credit bonds were issued with a total amount of RMB1,279bn, an 11.1% yoy decrease [17]. - **Company - Specific News**: Adani Energy Solutions plans a USD500mn bond issue, Greenko Energy raised INR48bn (cUSD524mn), Road King sold property interests, Sun Hung Kai settled a tender offer, China Vanke withdrew a REIT listing application and got a loan extension, Yuexiu Property expected FY25 profit to fall 90 - 95% yoy [17].

Market Overview - Global markets showed mixed performance, with the Hang Seng Index closing at 26,750, up 0.45% year-to-date, while the US Dow Jones fell by 0.58% [1][3] - The Chinese stock market saw gains, particularly in materials, consumer discretionary, and healthcare sectors, while energy and real estate lagged [3] Industry Insights - The Chinese pharmaceutical sector is experiencing a significant upward trend, with the MSCI China Healthcare Index rising 9.2% since early 2026, outperforming the MSCI China Index by 5.6% [4] - The trend of Chinese innovative drugs going overseas continues to gain momentum, with multiple business development (BD) transactions occurring in early 2026, indicating a strong market for overseas licensing [5] - Key transactions include the overseas rights granted by Rongchang Biopharma to AbbVie for RC148 and by Haisika for HSK39004, showcasing the clinical progress of these drugs [5] Company Analysis - China Ping An is projected to see a 12% increase in operating profit to RMB 135.9 billion in 2025, driven by improvements in life and health insurance segments [7] - The new business value (NBV) is expected to grow by 42% year-on-year to RMB 40.4 billion, with a strong performance anticipated in the first quarter of 2026, particularly in the bancassurance channel [8] - The target price for China Ping An has been raised to HKD 90, reflecting adjustments in profit and NBV growth forecasts, with the company currently trading at 0.71 times FY26E P/EV [8]